Pharmaceutical manufacturers are padding their wallets while rural families and retirees are squeezed by a system designed to benefit shareholders, not patients,” writes Tonja Hanson in an op-ed.

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

The Trump administration is experiencing some cognitive dissonance: The new president’s Justice Department is going to bat ...

The National Board of Revenue (NBR) has exempted advance tax on the import of raw materials used to manufacture cancer drugs, ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.

"Competition plays a crucial role in determining drug prices. When a new cancer drug is introduced by a single manufacturer, its cost is typically high due to research and development costs.

New measures will affect 40 essential drug therapies. Sofia aims to reduce bureaucratic obstacles to their sale and distribution.

In a notification issued on Sunday, the NBR said it had slashed the tax at source on the import of ingredients for oncology ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Under the deal, Sun Pharma will buy the outstanding shares of the Massachusetts-based company for $4.10 each, representing a premium of approximately 66% to Checkpoint’s closing share price last ...

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to ...